1 However, few studies examined the CV risk of uricosuric agents.

2                                              Uricosuric agents are also effective urate-lowering agen

3 thine oxidase inhibitor, allopurinol, or the uricosuric agent, benziodarone.

4                Benzbromarone (BBR), a potent uricosuric agent for the management of gout, is known to

5      This review considers the potential for uricosuric agents from the perspective of recent progres

6    For similar levels of urate lowering, the uricosuric agent probenecid had no effect on endothelial

7                                     Although uricosuric agents provide the most time-honoured approac

8 erging therapies, including pegloticase, the uricosuric agent RDEA596, and the interleukin-1 inhibito

9 f diuretics, beta-blockers, allopurinol, and uricosuric agents, self-reported hypertension and gout,

10                       Unlike other available uricosuric agents, the requirement for Cys-32 is unique

11 tablished that benzbromarone (BBR), a potent uricosuric agent used in the management of gout, irrever